Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Category
Cancer
Sub Category
Lung
Study Name
Merck Keynote MK3475-671: A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable IIB or IIIA Non-small Cell Lung Cancer
Principal Investigator
Gordan Srkalovic MD, PhD
Study Information
https://www.clinicaltrials.gov/ct2/show/NCT03425643?term=Merck+Keynote+MK3475-671&rank=1
Contact for Questions
Nurse - Tracy 517-364-2835

Site view: at a glance